Literature DB >> 30685591

NTCP S267F variant associates with decreased susceptibility to HBV and HDV infection and decelerated progression of related liver diseases.

Mai Thanh Binh1, Nghiem Xuan Hoan1, Hoang Van Tong2, Bui Tien Sy3, Ngo Tat Trung3, C-Thomas Bock4, Nguyen Linh Toan5, Le Huu Song3, Mai Hong Bang6, Christian G Meyer7, Peter G Kremsner8, Thirumalaisamy P Velavan9.   

Abstract

OBJECTIVES: To determine potential associations of the rs2296651 variant (c.800C>T, S267F) of NTCP with HBV and HBV plus concomitant HDV infection as well as with the progression of related liver diseases.
METHODS: The S267F variant was genotyped by DNA sequencing in 620 HBV-infected patients and 214 healthy controls (HCs). Among the patients, 450 individuals were tested for HDV by a nested PCR assay. Logistic regression was applied to examine the association.
RESULTS: The S267F variant was found more frequently among HCs (16%) compared to HBV-infected (6%) and HBV-HDV co-infected patients (3%) (HBV patients vs HC: OR=0.32, P=0.00002 and HDV patients vs. HC: OR=0.17, P=0.018). The frequency of S267F variant was inversely correlated with CHB, LC or HCC patients compared with HCs (OR=0.31, P=0.001; OR=0.32, P=0.013; OR=0.34, P=0.002, respectively). S267F variant was also associated with decreased risk of the development of advanced liver cirrhosis (LC) and hepatocellular carcinoma (HCC) (Child B and C vs. Child A, OR=0.26, adjusted P=0.016; BCLC B,C,D vs. BCLC A, OR=0.038, P=0.045, respectively). In addition, patients with the genotype CT had lower levels of AST, ALT, total and direct bilirubin as well as higher platelet counts, indicating an association with a more favorable clinical outcome.
CONCLUSION: The NTCP S267F variant of the SLC10A1 gene exhibits protective effects against HBV and HDV infection and is associated with a reduced risk of developing to advanced stages of LC and HCC.
Copyright © 2019 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  HBV; HDV; Liver diseases; NTCP; S267F

Mesh:

Substances:

Year:  2019        PMID: 30685591     DOI: 10.1016/j.ijid.2019.01.038

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  9 in total

1.  Hepatic Expression of the Na+-Taurocholate Cotransporting Polypeptide Is Independent from Genetic Variation.

Authors:  Roman Tremmel; Anne T Nies; Barbara A C van Eijck; Niklas Handin; Mathias Haag; Stefan Winter; Florian A Büttner; Charlotte Kölz; Franziska Klein; Pascale Mazzola; Ute Hofmann; Kathrin Klein; Per Hoffmann; Markus M Nöthen; Fabienne Z Gaugaz; Per Artursson; Matthias Schwab; Elke Schaeffeler
Journal:  Int J Mol Sci       Date:  2022-07-05       Impact factor: 6.208

2.  Efficacy and Safety of Bulevirtide plus Tenofovir Disoproxil Fumarate in Real-World Patients with Chronic Hepatitis B and D Co-Infection.

Authors:  Toni Herta; Magdalena Hahn; Melanie Maier; Janett Fischer; Johannes Niemeyer; Mario Hönemann; Albrecht Böhlig; Florian Gerhardt; Aaron Schindler; Jonas Schumacher; Thomas Berg; Johannes Wiegand; Florian van Bömmel
Journal:  Pathogens       Date:  2022-04-27

3.  Tyrosine 146 of the Human Na+/Taurocholate Cotransporting Polypeptide (NTCP) Is Essential for Its Hepatitis B Virus (HBV) Receptor Function and HBV Entry into Hepatocytes.

Authors:  Dariusz Zakrzewicz; Regina Leidolf; Sebastian Kunz; Simon Franz Müller; Anita Neubauer; Silke Leiting; Nora Goldmann; Felix Lehmann; Dieter Glebe; Joachim Geyer
Journal:  Viruses       Date:  2022-06-09       Impact factor: 5.818

4.  NTCP gene polymorphisms and hepatitis B virus infection status in a Ghanaian population.

Authors:  Eric Nyarko; Christian Obirikorang; W K B A Owiredu; Evans Asamoah Adu; Emmanuel Acheampong; Freeman Aidoo; Emmanuel Ofori; Bright Selorm Addy; Henry Asare-Anane
Journal:  Virol J       Date:  2020-07-03       Impact factor: 4.099

5.  Mechanistic insights into the inhibition of NTCP by myrcludex B.

Authors:  Joanne M Donkers; Monique D Appelman; Stan F J van de Graaf
Journal:  JHEP Rep       Date:  2019-08-01

Review 6.  Roles of Farnesyl-Diphosphate Farnesyltransferase 1 in Tumour and Tumour Microenvironments.

Authors:  Nguyen Thi Ha; Chang Hoon Lee
Journal:  Cells       Date:  2020-10-25       Impact factor: 6.600

7.  The NTCP p.Ser267Phe Variant Is Associated With a Faster Anti-HBV Effect on First-Line Nucleos(t)ide Analog Treatment.

Authors:  Lina Wu; Wenxiong Xu; Xuejun Li; Ying Liu; Lu Wang; Shu Zhu; Fangji Yang; Chan Xie; Liang Peng
Journal:  Front Pharmacol       Date:  2021-02-24       Impact factor: 5.810

8.  The characteristic of the synonymous codon usage and phylogenetic analysis of hepatitis B virus.

Authors:  Xiaoming Qi; Chaojun Wei; Yonghong Li; Yu Wu; Hui Xu; Rui Guo; Yanjuan Jia; Zhenhao Li; Zhenhong Wei; Wanxia Wang; Jing Jia; Yuanting Li; Anqi Wang; Xiaoling Gao
Journal:  Genes Genomics       Date:  2020-05-27       Impact factor: 1.839

Review 9.  Multitasking Na+/Taurocholate Cotransporting Polypeptide (NTCP) as a Drug Target for HBV Infection: From Protein Engineering to Drug Discovery.

Authors:  Dariusz Zakrzewicz; Joachim Geyer
Journal:  Biomedicines       Date:  2022-01-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.